Actavis Acquires Forest Laboratories For $25 Billion

Pharmaceutical giant Actavis confirmed on Tuesday that it had purchased Forest Laboratories for $25 billion in a deal that involved cash and stock. The deal would make Actavis a global producer of both generic and brand drugs. While Actavis has long focused on generic drugs, Forest has been successful with branded products such as Lexapro and Namenda.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news